RavenQuest BioMed Inc.
RVVQF · OTC
10/31/2018 | 10/31/2017 | 10/31/2016 | 10/31/2015 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -0.00 | -63.91 | -21.57 |
| FCF Yield | -37.50% | -5.83% | -0.08% | -0.05% |
| EV / EBITDA | -2.76 | -12.67 | -492.66 | -513.81 |
| Quality | ||||
| ROIC | -47.28% | -8.23% | 19.50% | 26.11% |
| Gross Margin | 63.75% | 13.04% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.36 | 0.76 | 0.40 | 0.26 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -830.24% | -7,639.95% | -64.61% | 46.17% |
| Safety | ||||
| Net Debt / EBITDA | -0.47 | 1.00 | -1.02 | -0.66 |
| Interest Coverage | -9.02 | -4.37 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.51 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -642.66 | 597.75 | 0.00 | 0.00 |